Welcome to our dedicated page for Zoetis SEC filings (Ticker: ZTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zoetis Inc. filings document the animal health company's operating results, capital returns, financing activity and governance disclosures. Recent 8-K reports furnish quarterly and annual financial results, guidance, dividend declarations, investor presentations and other Regulation FD disclosures.
The company's proxy materials address board and compensation matters, including executive pay and equity-award disclosures. Other filings record its New York Stock Exchange-listed common stock and debt financing, including a private offering of convertible senior notes, related indenture terms and capped call transactions.
Zoetis Inc. (ZTS) disclosed that its Chief Executive Officer and Director acquired 389.0627 phantom stock units on 10/10/2025 at $46.71 under the Zoetis Supplemental Savings Plan.
Each phantom unit’s value is tied to Zoetis common stock plus a cash-equivalent component and is settled in cash after separation from service.
Following this transaction, the reporting person beneficially owned 58,043.5681 derivative securities. The derivative position references 128.7869 shares of Zoetis common stock.
Zoetis (ZTS) disclosed a Form 4 showing its Executive Vice President acquired derivative securities tied to company stock. On 10/10/2025, the officer acquired 158.5078 phantom stock units at a price of $46.71, bringing total derivative holdings to 1,098.1566 units. These units reference Zoetis common stock; the filing lists an underlying amount of 52.469 shares for this transaction.
Per the plan terms, the phantom stock units are settled in cash following separation from service and may be reallocated among plan investment options subject to company limitations.
Zoetis (ZTS) Executive Vice President filed a Form 4 reporting an acquisition of phantom stock units under the Zoetis Supplemental Savings Plan on 10/10/2025. The filing shows the addition of 149.8609 phantom stock units at a derivative security price of $46.71, bringing total derivative holdings to 5,226.362 units, held directly.
These phantom stock units are settled in cash after separation from service, and their value tracks Zoetis common stock plus a small cash-equivalent component. Transfers among plan investment funds are permitted, subject to plan limits.
Zoetis Inc. declared a cash dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on December 2, 2025 to shareholders who are on record as of the close of business on October 31, 2025. This reflects the company’s ongoing practice of returning cash to common stock holders through regular quarterly dividends.
Roxanne Lagano, Executive Vice President of Zoetis Inc. (ZTS), reported a charitable gift of 700 shares of Zoetis common stock on 09/15/2025. The transaction is coded as a gift and carried no price. After the gift, Ms. Lagano directly beneficially owns 14,429 shares. She also holds the equivalent of 819.698 shares indirectly through the Zoetis Savings Plan (401(k)) as of June 30, 2025. The Form 4 was signed by an attorney-in-fact on 09/16/2025. The filing provides ownership levels and documents the charitable disposition; no option or derivative activity is reported.
Zoetis Inc. filed an 8-K reporting a material event: a Revolving Credit Agreement dated August 27, 2025 among Zoetis, the lenders, the issuing banks and JPMorgan Chase Bank, N.A. as administrative agent. The document identifies the agreement date and parties and includes an interactive cover page in the Inline XBRL file. The filing is signed by Roxanne Lagano, Executive Vice President, General Counsel and Corporate Secretary. The filing text does not disclose the credit facility’s economic terms, commitment size, maturity, covenants, or borrowing details.
Zoetis Inc. disclosed that it entered into an Underwriting Agreement on August 11, 2025 for a public debt offering of two senior note tranches. The company is issuing $850,000,000 aggregate principal amount of 4.150% Senior Notes due 2028 and $1,000,000,000 aggregate principal amount of 5.000% Senior Notes due 2035. These Notes are issued under Zoetis’s existing indenture with Deutsche Bank Trust Company Americas, as supplemented on August 18, 2025, and are registered under an effective Form S-3 shelf registration statement. Related agreements, indentures, note forms, and legal opinions are filed as exhibits.
Zoetis Inc. (ZTS) filed an automatic shelf registration statement on Form S-3 as a well-known seasoned issuer, enabling the company and future selling securityholders to issue an indeterminate amount of securities, including debt, common and preferred stock, warrants, depositary shares, purchase contracts/units, guarantees and hybrid instruments.
Each issuance will be detailed in a later prospectus supplement; no specific size, price or timing is disclosed in this filing. Net proceeds, when and if raised, may fund general corporate purposes such as working capital, capital expenditures, acquisitions and debt refinancing.
The prospectus summarises indenture terms—pari-passu ranking, optional redemption, covenants limiting certain liens and sale-leasebacks, standard events of default and defeasance options. The company re-confirms its NYSE listing (symbol “ZTS”) and notes 443.9 million common shares outstanding (authorised: 6 billion).
Risk factors are incorporated by reference and cover competitive pressures, supply-chain disruption, economic conditions, regulation, FX volatility and substantial indebtedness. The filing involves no immediate security issuance; it simply preserves capital-raising flexibility.
Zoetis (ZTS) Q2-25 10-Q highlights:
- Revenue rose 4.2% YoY to $2.46 bn; H1-25 up 2.8% to $4.68 bn.
- Net income climbed 15.1% YoY to $718 m; diluted EPS $1.61 vs $1.37. H1 EPS $3.02 (+13%).
- Gross margin improved to 73.6% (cost of sales down 2.8% despite higher volume).
- Operating expenses were mixed: SG&A +6.2%, R&D flat, amortization -6.3%. Restructuring & A&D costs fell to $30 m from $42 m.
- Effective tax rate 20.4% vs 20.0%.
- Segment trends: Companion animal +8.4% to $1.79 bn; Livestock -8.1% to $638 m. Strongest products: Parasiticides (+12%), Vaccines (+13%), Dermatology (+11%). Anti-infectives -17%.
- Cash $1.44 bn (-$552 m YTD) after $781 m buybacks and $447 m dividends. Debt unchanged at $6.65 bn; net debt up.
- Treasury shares outstanding 57.9 m; $4.9 bn remains on $6 bn repurchase authorization.
- Inventory rose 5.8% YoY to $2.44 bn; restructuring accrual $20 m.
- IRS audit could add up to $450 m tax liability; uncertain timing.
Overall, Zoetis delivered double-digit EPS growth driven by companion animal strength and margin expansion, while livestock softness, rising inventories and tax/audit uncertainties warrant monitoring.